
Irinotecan Liposome Injection Gets FDA Fast Track Designation for Second-Line Small Cell Lung Cancer
FDA grants fast track designation to irinotecan liposome injection (Onivyde; MM-398) as second-line monotherapy for patients with small cell lung cancer whose disease progressed following a platinum-based chemotherapy regimen.





























